Dostinex: Effective Prolactin Regulation Therapy
| Product dosage: 0.25mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 32 | $3.06 | $98.04 (0%) | 🛒 Add to cart |
| 48 | $2.85 | $147.06 $136.74 (7%) | 🛒 Add to cart |
| 56 | $2.78
Best per pill | $171.57 $155.66 (9%) | 🛒 Add to cart |
| Product dosage: 0.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 32 | $5.86 | $187.48 (0%) | 🛒 Add to cart |
| 48 | $5.63 | $281.22 $270.04 (4%) | 🛒 Add to cart |
| 56 | $5.56
Best per pill | $328.09 $311.32 (5%) | 🛒 Add to cart |
Synonyms | |||
Dostinex (cabergoline) is a prescription medication specifically formulated for the treatment of hyperprolactinemia, a condition characterized by elevated levels of the hormone prolactin. As a dopamine receptor agonist, it directly targets the underlying physiological mechanism responsible for excessive prolactin secretion. This medication is recognized for its high efficacy and favorable pharmacokinetic profile, offering patients a reliable therapeutic option. Clinical use is supported by extensive research and long-standing application in endocrinology and reproductive medicine.
Features
- Active ingredient: Cabergoline 0.5 mg per tablet
- Pharmacological class: Dopamine D2 receptor agonist
- Administration: Oral tablet formulation
- Half-life: Approximately 63–69 hours
- Bioavailability: 40–50% following oral administration
- Excretion: Primarily fecal (72%) with minor renal elimination
- Manufacturer: Pfizer Pharmaceuticals
- FDA approval status: Approved for hyperprolactinemia indications
Benefits
- Effectively reduces elevated prolactin levels to within normal physiological range
- Restores ovulatory cycles and fertility in women with hyperprolactinemic amenorrhea
- Alleviates galactorrhea (inappropriate lactation) in both male and female patients
- Reduces prolactinoma tumor size in cases of pituitary adenomas
- Demonstrates prolonged therapeutic effect permitting twice-weekly dosing
- Shows generally favorable tolerability profile compared to older ergot-derived agonists
Common use
Dostinex is primarily indicated for the treatment of hyperprolactinemic disorders, including idiopathic hyperprolactinemia and prolactin-secreting pituitary adenomas (prolactinomas). It is employed in the management of associated symptoms such as infertility, amenorrhea, oligomenorrhea, galactorrhea, and hypogonadism. Off-label applications include Parkinson’s disease therapy (at higher doses) and suppression of physiological lactation, though these uses require careful medical supervision.
Dosage and direction
The initial recommended dosage is 0.25 mg twice weekly, which may be increased gradually by 0.25 mg per week at monthly intervals based on prolactin level monitoring. Administration typically occurs with food to minimize potential gastrointestinal discomfort. Maximum therapeutic dosage generally should not exceed 1 mg twice weekly, though individual titration is essential. Dose adjustments should be made under strict medical supervision with regular assessment of prolactin levels and clinical response.
Precautions
Patients should undergo comprehensive cardiovascular evaluation before initiation, including echocardiography to rule out valvular heart disease. Regular monitoring of blood pressure is recommended, particularly during dose titration. Caution is advised in patients with hepatic impairment, requiring possible dose reduction. Patients should be advised about potential dizziness or somnolence that could impair driving or operating machinery. Pregnancy testing is recommended before initiation in women of childbearing potential.
Contraindications
Dostinex is contraindicated in patients with hypersensitivity to cabergoline or any ergot derivatives. It should not be used in patients with uncontrolled hypertension, history of cardiac valvular disease, or clinically significant pulmonary fibrosis. Concomitant use with other dopamine antagonists is contraindicated. The medication is not recommended for patients with severe hepatic impairment without careful risk-benefit assessment.
Possible side effects
Common adverse reactions (>10% incidence) include nausea, headache, dizziness, and fatigue. Less frequent effects (1-10%) may comprise constipation, abdominal pain, dyspepsia, vomiting, and orthostatic hypotension. Rare but serious potential side effects include cardiac valvulopathy, pleural effusion, pulmonary fibrosis, and psychiatric disturbances including impulse control disorders. Most side effects are dose-dependent and often diminish with continued therapy or dose adjustment.
Drug interaction
Concomitant use with antipsychotics (particularly D2 antagonists) may diminish therapeutic efficacy. Macrolide antibiotics and CYP3A4 inhibitors may increase cabergoline plasma concentrations. Antihypertensive agents may potentiate orthostatic hypotension. Serotonin agonists (triptans) may increase risk of serotonin syndrome. Dopamine antagonists including metoclopramide and phenothiazines should generally be avoided during therapy.
Missed dose
If a scheduled dose is missed, patients should take it as soon as remembered unless it is nearly time for the next dose. In such cases, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling of doses to compensate for missed administration is not recommended. Consistent adherence to the prescribed regimen is important for maintaining stable prolactin suppression.
Overdose
Symptoms of overdose may include severe nausea, vomiting, hypotension, hallucinations, and psychosis. Management involves symptomatic and supportive care, including gastric lavage if ingestion was recent. Maintenance of blood pressure may require volume expansion or vasopressor therapy. There is no specific antidote for cabergoline overdose. Hemodialysis is unlikely to be effective due to high protein binding and extensive tissue distribution.
Storage
Store at room temperature (15-30°C or 59-86°F) in the original container, protected from light and moisture. Keep tightly closed and out of reach of children. Do not use beyond the expiration date printed on packaging. Avoid storage in bathrooms or other areas with high humidity. Proper disposal of unused medication should follow local regulations for pharmaceutical waste.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Treatment decisions must be made by qualified healthcare professionals based on individual patient circumstances. Patients should not alter dosage or discontinue medication without consulting their prescribing physician. The prescribing information provided here may not include all possible uses, directions, precautions, or interactions.
Reviews
Clinical studies demonstrate Dostinex’s efficacy in normalizing prolactin levels in 80-90% of patients with microprolactinomas and 70-80% with macroprolactinomas. Long-term follow-up studies indicate sustained efficacy with maintenance of normoprolactinemia in most patients. Patient satisfaction surveys report significant improvement in quality of life measures, particularly regarding restoration of fertility and resolution of galactorrhea. The twice-weekly dosing regimen is frequently cited as a significant advantage over daily therapies, improving adherence and convenience.